SCHEMBL5574062

SCHEMBL5574062

CC(C)(C)OC(=O)N1CCC(CC(CC2CCN(C(=O)OC(C)(C)C)CC2)C(=O)O)CC1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.51
PKM P14618 1/20 0.51
HPGD P15428 1/20 0.49
GPR119 Q8TDV5 4/20 0.47
RECQL P46063 1/20 0.47
EPHX1 P07099 1/20 0.47
USP2 O75604 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
FAAH O00519 1/20 0.44
NR1H2 P55055 1/20 0.43
MAPT P10636 2/20 0.43
NPC1 O15118 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
THRB P10828 1/20 0.43
YAP1 P46937 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7141623 0.93 KDM4E (0.48) KDM4EPKMHPGDGPR119RECQL
SCHEMBL6060188 0.92 CPN1 (0.49) KDM4EPKMHPGDGPR119RECQL
SCHEMBL7419160 0.90 CPN1 (0.48) KDM4EPKMHPGDGPR119RECQL
SCHEMBL7353432 0.89 KDM4E (0.52) KDM4EPKMHPGDGPR119RECQL
SCHEMBL1833049 0.87 KDM4E (0.50) KDM4EPKMHPGDGPR119RECQL
SCHEMBL7943442 0.87 KDM4E (0.50) KDM4EPKMHPGDGPR119RECQL
SCHEMBL7497123 0.87 KDM4E (0.50) KDM4EPKMHPGDGPR119RECQL
SCHEMBL3654209 0.87 KDM4E (0.50) KDM4EPKMHPGDGPR119RECQL
SCHEMBL18099946 0.85 KDM4E (0.49) KDM4EPKMHPGDGPR119RECQL
SCHEMBL27641135 0.85 KDM4E (0.49) KDM4EPKMHPGDGPR119RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1057815-B1 CYCLIC AMIDE COMPOUNDS KOWA CO (JP) 2007-09-05 EP disclosed
US-6645957-B2 Useful in preventing and treating allergic immunological diseases; treating asthma, atopic dermatitis, allergic rhinitis, inflammatory large bowel disease, contact dermatitis KOWA CO., LTD. (JP) 2003-11-11 US disclosed
US-20030096828-A1 Cyclic amide compound KOWA CO., LTD. (JP) 2003-05-22 US disclosed
US-6448242-B1 COMPOUND HAVING A STRONG INHIBITORY EFFECT ON THE PRODUCTION OF AN IGE ANTIBODY; ANTIALLERGENS KOWA CO., LTD. (JP) 2002-09-10 US disclosed
EP-1057815-A1 CYCLIC AMIDE COMPOUNDS Kowa Co., Ltd. (JP) 2000-12-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096828-A1 Cyclic amide compound CMA1, HRH2, HRH4 KDM4E 218/4885PKM 4761/4885HPGD 1987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.